Beijing Science Sun Pharmaceutical Turns Profit in 2025, Reports Net Income of 14.571 Million Yuan

Stock News03-30

Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) has released its annual report for 2025. The company achieved operating revenue of 405 million yuan, representing a decrease of 2.82% compared to the previous year. Net profit attributable to shareholders of the listed company was 14.571 million yuan, marking a turnaround to profitability. However, the net profit attributable to shareholders after deducting non-recurring gains and losses showed a loss of 26.9904 million yuan. Basic earnings per share were 0.03 yuan. Furthermore, the company proposed a cash dividend of 0.3 yuan per 10 shares (tax inclusive). During the reporting period, the company actively advanced the production and sales of clinically scarce and easily short-supplied products. It also progressed with the validation process for its Liangshuihe Erjie facility, accelerating tasks related to product site changes, technology transfers, and GMP compliance inspections.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176790334?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176790334","market":"sh","top_or_hot":-1,"title":"Beijing Science Sun Pharmaceutical Turns Profit in 2025, Reports Net Income of 14.571 Million Yuan","media":"Stock News","content":"<p>Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) has released its annual report for 2025. The company achieved operating revenue of 405 million yuan, representing a decrease of 2.82% compared to the previous year. Net profit attributable to shareholders of the listed company was 14.571 million yuan, marking a turnaround to profitability. However, the net profit attributable to shareholders after deducting non-recurring gains and losses showed a loss of 26.9904 million yuan. Basic earnings per share were 0.03 yuan. Furthermore, the company proposed a cash dividend of 0.3 yuan per 10 shares (tax inclusive). During the reporting period, the company actively advanced the production and sales of clinically scarce and easily short-supplied products. It also progressed with the validation process for its Liangshuihe Erjie facility, accelerating tasks related to product site changes, technology transfers, and GMP compliance inspections.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Science Sun Pharmaceutical Turns Profit in 2025, Reports Net Income of 14.571 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Science Sun Pharmaceutical Turns Profit in 2025, Reports Net Income of 14.571 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) has released its annual report for 2025. The company achieved operating revenue of 405 million yuan, representing a decrease of 2.82% compared to the previous year. Net profit attributable to shareholders of the listed company was 14.571 million yuan, marking a turnaround to profitability. However, the net profit attributable to shareholders after deducting non-recurring gains and losses showed a loss of 26.9904 million yuan. Basic earnings per share were 0.03 yuan. Furthermore, the company proposed a cash dividend of 0.3 yuan per 10 shares (tax inclusive). During the reporting period, the company actively advanced the production and sales of clinically scarce and easily short-supplied products. It also progressed with the validation process for its Liangshuihe Erjie facility, accelerating tasks related to product site changes, technology transfers, and GMP compliance inspections.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"","article_id":"1176790334","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176790334","pubTimestamp":1774861345,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) has released its annual report for 2025. The company achieved operating revenue of 405 million yuan, representing a decrease of 2.82% compared...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300485":"赛升药业","BK0012":"证金概念","BK0046":"生物疫苗","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"北京科学太阳药业2025年扭亏为盈净收入1457.1万元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300485":1},"content_text":"Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) has released its annual report for 2025. The company achieved operating revenue of 405 million yuan, representing a decrease of 2.82% compared to the previous year. Net profit attributable to shareholders of the listed company was 14.571 million yuan, marking a turnaround to profitability. However, the net profit attributable to shareholders after deducting non-recurring gains and losses showed a loss of 26.9904 million yuan. Basic earnings per share were 0.03 yuan. Furthermore, the company proposed a cash dividend of 0.3 yuan per 10 shares (tax inclusive). During the reporting period, the company actively advanced the production and sales of clinically scarce and easily short-supplied products. It also progressed with the validation process for its Liangshuihe Erjie facility, accelerating tasks related to product site changes, technology transfers, and GMP compliance inspections.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176790334","isCrawlerRequest":true}